A digital platform to support mental health in people with cancer and their families
Tests an online platform for mental health care in cancer patients, families and clinicians.
Plain-language title generated from the registry record
Registry title: Digital Solutions for bEtter cAre
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a current or past cancer diagnosis, their caregivers and family members, and healthcare professionals who work in oncology or psycho-oncology.
- Age
- 12 years and older (minimum age 12 years).
- Sex
- All sexes can join.
- Disease stage
- A current or previous cancer diagnosis. The record gives no stage.
Main reasons for not taking part
- Healthcare professionals with limited contact with oncology patients
- Not enough knowledge of the local language
- Severe cognitive impairment or mental disorder that prevents taking part, or cannot give informed consent (as judged by the clinician)
- Cannot understand the study materials (as judged by the clinician)
- Physical or psychological impairment that prevents taking part in focus groups (as judged by the clinician)
Read by machine on 9 November 2026.
Where in Spain
- Catalan Institute of OncologyBarcelona, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- European Institute of Oncology
- Trial code
- NCT07416513
- Record updated
- 18 February 2026
- Original description
The target population includes cancer patients, caregivers, family members, healthcare providers and mental health specialists, who will be the primary end-users of the Althea platform. For patients, survivors, caregivers, and family members, the sample variables include age, gender, type and stage of disease, and time since the first diagnosis. The healthcare professionals that will be involved in this study are those who attend to oncological patients, with sample variables such as age, gender, professional role, and prior experience and training in oncology or psycho-oncology.Read full original descriptionShow less
ALTHEA: tAckLing menTal Health Cancer Patients and Their Families: Digital Solutions for bEtter cAre
The target population includes cancer patients, caregivers, family members, healthcare providers and mental health specialists, who will be the primary end-users of the Althea platform. For patients, survivors, caregivers, and family members, the sample variables include age, gender, type and stage of disease, and time since the first diagnosis. The healthcare professionals that will be involved in this study are those who attend to oncological patients, with sample variables such as age, gender, professional role, and prior experience and training in oncology or psycho-oncology.
Inclusion: HEALTHCARE PROFESSIONALS:; Healthcare professionals actually working in oncology and/or psychooncology; Teachers of paediatric cancer patients; ADULT POPULATION:; Patients with a current or previous cancer diagnosis; Adequate language proficiency,; Able to provide informed consent; PAEDIATRIC POPULATION:; Older than 12 years of age; Patients with a current or previous cancer diagnosis; Adequate language proficiency; Legal guardians of paediatric cancer patients able to provide informed consent; CAREGIVERS:; Caregivers and/or family members of cancer patients who lived or assist the loved ones with a current or previous cancer diagnosis in the cancer journey; Adequate language proficiency; Able to provide informed consent; Caregivers and/or family members of paediatric cancer patients under 12 years of age.
Exclusion: Severe cognitive impairment, and/or mental disorders that prohibited their participation in the study or inadequate verbal skills that may render them incapable of informed consent (as evaluated by the clinician); Physical or psychological impairment that prohibits their participation in focus groups (as evaluated by the clinician); Healthcare professionals with limited oncology patient contact; Insufficient knowledge of the local language; Inability to understand the study materials (as evaluated by the clinician).